IQVIA%e2%80%99s HTA Accelerator</a> provides instant insights into payer decision-making from HTA reports of more than 100 agencies in 32 countries across all therapeutic areas. Based on our data extraction parameters we’ve identified 433 single-arm clinical trial submissions to HTA bodies, looking back to 2011. Starting from initial submissions in 2011, we see a subsequent 13-fold increase to 2019, mostly in oncology indications (see Figure 1). </p>" /> IQVIA%e2%80%99s HTA Accelerator</a> provides instant insights into payer decision-making from HTA reports of more than 100 agencies in 32 countries across all therapeutic areas. Based on our data extraction parameters we’ve identified 433 single-arm clinical trial submissions to HTA bodies, looking back to 2011. Starting from initial submissions in 2011, we see a subsequent 13-fold increase to 2019, mostly in oncology indications (see Figure 1). </p>" />
Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Integrated Global Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

IQVIA TECHNOLOGIES

"Harness technology for a healthier world.

EXPLORE MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety and quality.

COMPLIANCE OVERVIEW
Integrated Global Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2023

READ MORE

Webinar

"Global Consumer Health Trends 2023 Webinar Series

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • Connected Intelligence
  • AI & Machine Learning
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Genomics
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
AI & Machine Learning with a healthcare IQ.

Artificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
Unlock the power of genomic research.

IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
Securing market access with single-arm trial data
What is the optimal external comparator strategy?
Dony Patel, Director, IQVIA
Jun 10, 2021
  • Blogs
  • Securing market access with single-arm trial data

R&D pipelines are rich with innovation in areas of high unmet need, driving a surge in promising new treatments for patients with niche and rare diseases. Under pressure to accelerate approval, regulators are increasingly authorizing use on the basis of single-arm efficacy data. Thus, HTA submissions based on single-arm trial data are rapidly increasing and external comparators are becoming essential, but what type of external comparator approach is best? Here, we explore trends in HTA submissions and outcomes that can inform your strategy.

IQVIA’s HTA Accelerator provides instant insights into payer decision-making from HTA reports of more than 100 agencies in 32 countries across all therapeutic areas. Based on our data extraction parameters we’ve identified 433 single-arm clinical trial submissions to HTA bodies, looking back to 2011. Starting from initial submissions in 2011, we see a subsequent 13-fold increase to 2019, mostly in oncology indications (see Figure 1).

Single Arm trial submissions to HTA bodies

Reproduced from: Patel, D et al. Use of External Comparators for Health Technology Assessment (HTA) Submissions Based on Single-Arm Trials. Value in Health, 2021, In Press.

Trend towards real world data external comparators

External comparators are rapidly becoming an expected part of non-RCT HTA submissions. Our analysis shows that since 2011, 52% (226/433) of submissions contained some type of external comparator data and the proportion of submissions using no external comparator remains relatively unchanged. However, the type of external comparator datasets used is changing. In the latest 5-year period (2015-19), use of real world data (RWD) external comparators increased by 22%, whereas use of prior trial data as an external comparator decreased by 14%.

Which type of external comparator dataset will most likely lead to a successful HTA outcome? This is hard to say definitively due to the multidimensional nature of HTA decision-making and orphan status, but our analysis shows that there are clear trends in acceptability. Over the last 5 years (Between 2015-17 and 2018-19), the acceptance rate for RWD external comparators increased by 20% while acceptance of prior trial external comparators decreased by 10%, and acceptance of HTA submissions with no external comparator submissions decreased 16%. (see Figure 2).

External Comparator use and HTA recommendation for Single Arm trial

Which methodological approach for your external comparator study?

External comparator studies can vary in approach, not only by type of data source but also by method of the comparison. We analyzed whether companies where using a simple, non-statistically adjusted (or ‘naïve’) comparison approach or if statistical adjustment methods were used (either direct propensity score methods or indirect population adjustment methods) (Figure 3).

It is often hard to determine the statistical approach used from HTA appraisals as the level of information varies on these methods. However, from what we could observe, adjusted methods represented only 29% (66) of all external comparator SAT submissions, but has increased by 14% over the last 5 years. 61% (137) submissions were presumed to use ECs in a naïve comparison context. The use of naïve comparisons decreased 8% in the last 5 years.

While this trend may indicate that adjusted methods will be expected for HTA acceptance, we did not see a significant difference in acceptance in our data. We expect this to change as we see more frequent critique of naïve comparison approaches from HTAs.

External Comparator use and HTA recommendation for Single Arm trial

Planning your external comparator strategy

We see a trend towards better results when using external comparators and particularly RWD external comparators. However, the presence of an external comparator does not guarantee HTA acceptance. Based on our analysis of post-HTA conclusions, acceptability of the data and appropriateness of the analytical method were important considerations, underscoring the multidimensional nature of HTA decision-making. How, then, can you decide which way to go?

A five-step strategic process

Choosing comparator cohorts isn’t easy. Standards of patient care can change over time and vary by country. Careful evaluation of past HTA decisions in your target indication(s) as well as early input from HTA stakeholders are critical. Before designing an external comparator study, we recommend a strategic approach

  • Establish the need for an external comparator
  • Identify the factors that will drive success
  • Determine the right external comparator group
  • Collect the external comparator data
  • Ensure the most appropriate methodology for comparison to your study data

IQVIA has a dedicated team of experts with significant experience working with manufacturers to define the strategy and methodology for external comparators supporting submissions to regulators and HTA bodies.

About IQVIA’s HTA Accelerator

IQVIAs HTA Accelerator tool contains over 34,000 HTA publications covering 41 countries and 100 HTA bodies published since 2011. Companies can review indication-specific, clinical evidence and comparators, economic analysis, HTA body critique and recommendations. It also features information about the use of RWE, the types of RWE used, the areas supported and the acceptance by HTA bodies. This enables a data-driven approach to your market access strategy and study design.

Source: Patel, D et al. Use of External Comparators for Health Technology Assessment (HTA) Submissions Based on Single-Arm Trials. Value in Health, 2021, In Press.

For further information contact Sam.Foster@iqvia.com or Dony.Patel@iqvia.com

Explore more in this recent ScienceDirect publication: View here.

Contact Us